Literature DB >> 20971816

CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.

Martin Schmidt-Hieber1, Martin Pérez-Andrés, Bruno Paiva, Juan Flores-Montero, Jose J Perez, Norma C Gutierrez, Maria-Belen Vidriales, Sergio Matarraz, Jesus F San Miguel, Alberto Orfao.   

Abstract

Aberrant CD117 expression is associated with a favorable outcome in multiple myeloma. We analyzed 106 patients with symptomatic multiple myeloma (n=50), smoldering multiple myeloma (n=38) and monoclonal gammopathy of undetermined significance (n=18) to elucidate biological features of CD117(+) versus CD117(-) monoclonal gammopathies. CD117(+) (mono)clonal plasma cells were detected in 30% symptomatic multiple myeloma, 45% smoldering multiple myeloma and 72% monoclonal gammopathy of undetermined significance patients. CD117 expression was associated with higher percentages of normal bone marrow plasma cells, CD117(+) myeloid precursors and CD38(+) B lymphocytes in all monoclonal gammopathies. Conversely, the number of bone marrow CD34(+) myeloid cells and peripheral blood neutrophils was reduced among CD117(+) multiple myeloma but not monoclonal gammopathy of undetermined significance patients. CD117 expression by (mono)clonal plasma cells is associated with uniquely altered patterns of production of hematopoietic bone marrow cells with decreased peripheral blood neutrophil counts and persistence of normal residual bone marrow plasma cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971816      PMCID: PMC3031704          DOI: 10.3324/haematol.2010.031872

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

1.  Expression of high amounts of the CD117 molecule in a case of B-cell non-Hodgkin's lymphoma carrying the t(14:18) translocation.

Authors:  P Bravo; B D Agustín; C Bellas; D González; C Cámara; I F Fuertes; J Almeida; R G Sanz; A Orfao; L Escribano
Journal:  Am J Hematol       Date:  2000-04       Impact factor: 10.047

2.  A phase II trial of imatinib in patients with refractory/relapsed myeloma.

Authors:  Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Susan M Geyer; Phillip R Greipp; S Vincent Rajkumar; Teresa Kimlinger; John A Lust; Rafael Fonseca; Jacob Allred; Thomas E Witzig
Journal:  Leuk Lymphoma       Date:  2006-01

Review 3.  Microenvironmental niches in the bone marrow required for B-cell development.

Authors:  Takashi Nagasawa
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

4.  CD117 expression in diffuse large B-cell lymphomas: fact or fiction?

Authors:  Efsevia Vakiani; Giorgio Cattoretti; Adriana I Colovai; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  Pathol Int       Date:  2005-11       Impact factor: 2.534

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Genetic abnormalities and patterns of antigenic expression in multiple myeloma.

Authors:  Gema Mateo; Mariana Castellanos; Ana Rasillo; Norma C Gutiérrez; Ma Angeles Montalbán; Ma Luisa Martín; Jesús Ma Hernández; Ma Consuelo López-Berges; Laura Montejano; Joan Bladé; Ma Victoria Mateos; Anna Sureda; Javier de la Rubia; Joaquín Díaz-Mediavilla; Atanasio Pandiella; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

7.  CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.

Authors:  Régis Bataille; Catherine Pellat-Deceunynck; Nelly Robillard; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  Leuk Res       Date:  2007-09-04       Impact factor: 3.156

Review 8.  Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis.

Authors:  L Escribano; M Ocqueteau; J Almeida; A Orfao; J F San Miguel
Journal:  Leuk Lymphoma       Date:  1998-08

9.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.

Authors:  Gema Mateo; M Angeles Montalbán; Maria-Belén Vidriales; Juan J Lahuerta; Maria V Mateos; Norma Gutiérrez; Laura Rosiñol; Laura Montejano; Joan Bladé; Rafael Martínez; Javier de la Rubia; Joaquín Diaz-Mediavilla; Anna Sureda; José M Ribera; José M Ojanguren; Felipe de Arriba; Luis Palomera; Maria J Terol; Alberto Orfao; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2008-04-28       Impact factor: 44.544

Review 10.  Recent advances in the understanding of mastocytosis: the role of KIT mutations.

Authors:  Alberto Orfao; Andrés C Garcia-Montero; Laura Sanchez; Luis Escribano
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

View more
  23 in total

Review 1.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

Review 2.  Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing.

Authors:  Megan J Fitzpatrick; Valentina Nardi; Aliyah R Sohani
Journal:  Skeletal Radiol       Date:  2021-03-09       Impact factor: 2.199

3.  Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.

Authors:  Sang-Yong Shin; Seung-Tae Lee; Hee-Jin Kim; Suk Jin Kim; Kihyun Kim; Eun Suk Kang; Sun-Hee Kim
Journal:  J Clin Lab Anal       Date:  2014-10-02       Impact factor: 2.352

4.  Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.

Authors:  T Paíno; B Paiva; J M Sayagués; I Mota; T Carvalheiro; L A Corchete; I Aires-Mejía; J J Pérez; M L Sanchez; P Barcena; E M Ocio; L San-Segundo; M E Sarasquete; R García-Sanz; M-B Vidriales; A Oriol; M-T Hernández; M-A Echeveste; A Paiva; J Blade; J-J Lahuerta; A Orfao; M-V Mateos; N C Gutiérrez; J F San-Miguel
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

5.  Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Authors:  P Arana; B Paiva; M-T Cedena; N Puig; L Cordon; M-B Vidriales; N C Gutierrez; F Chiodi; L Burgos; L-L Anglada; J Martinez-Lopez; M-T Hernandez; A-I Teruel; M Gironella; M-A Echeveste; L Rosiñol; R Martinez; A Oriol; J De la Rubia; A Orfao; J Blade; J-J Lahuerta; M-V Mateos; J-F San Miguel
Journal:  Leukemia       Date:  2017-11-03       Impact factor: 11.528

6.  Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?

Authors:  Sergio Matarraz; Bruno Paiva; María Diez-Campelo; Lucia López-Corral; Estefanía Pérez; Maria-Victoria Mateos; Pilar Giraldo; Miguel T Hernández; Jesús F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-04-17       Impact factor: 9.941

7.  Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Authors:  Martin Schmidt-Hieber; María Laura Gutiérrez; Martin Pérez-Andrés; Bruno Paiva; Ana Rasillo; Maria Dolores Tabernero; José Maria Sayagués; Antonio Lopez; Paloma Bárcena; María Luz Sanchez; Norma C Gutiérrez; Jesus F San Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

8.  Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Authors:  D Chiron; S Maïga; S Surget; G Descamps; P Gomez-Bougie; S Traore; N Robillard; P Moreau; S Le Gouill; R Bataille; M Amiot; C Pellat-Deceunynck
Journal:  Blood Cancer J       Date:  2013-06-07       Impact factor: 11.037

9.  Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients.

Authors:  Fanny Pojero; Alessandra Casuccio; Francesco Di Bassiano; Francesco Gervasi; Giuseppina Colonna Romano; Calogero Caruso
Journal:  Immun Ageing       Date:  2015-06-04       Impact factor: 6.400

Review 10.  Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms.

Authors:  Nadine Kutsch; Reinhard Marks; Richard Ratei; Thomas K Held; Martin Schmidt-Hieber
Journal:  Biomark Insights       Date:  2015-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.